Related Experiment Video
Updated: Feb 8, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Forestalling BRAF-Inhibitor Resistance in a Shocking Way
1Massachusetts General Hospital Cancer Center, Boston, Massachusetts. rsullivan7@mgh.harvard.edu.
Abstract:
Targeting BRAF in BRAF-mutant melanoma is highly effective, but most patients develop resistance. HSP90 has been implicated and identified as a therapeutic target. Ultimately, early-stage clinical investigation will be necessary to provide proof of principle of this approach and if appropriate randomized trials to confirm promising findings. Clin Cancer Res; 24(22); 5496-8. ©2018 AACR See related article by Eroglu et al., p. 5516.
Insights
Targeting BRAF in BRAF-mutant melanoma is effective, but resistance emerges. Heat shock protein 90 (HSP90) is a potential therapeutic target to overcome this resistance in melanoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- BRAF inhibitors are effective against BRAF-mutant melanoma.
- Acquired resistance limits the long-term efficacy of BRAF-targeted therapy.
- Heat shock protein 90 (HSP90) is implicated in resistance mechanisms.
Purpose of the Study:
- To investigate HSP90 as a potential therapeutic target in BRAF-mutant melanoma.
- To explore strategies to overcome resistance to BRAF inhibitors.
Main Methods:
- Review of existing literature on BRAF inhibitors and resistance in melanoma.
- Discussion of the role of HSP90 in cancer cell survival and drug resistance.
- Consideration of clinical trial designs for HSP90-targeted therapies.
Main Results:
- BRAF inhibition is a validated strategy for melanoma but is hampered by resistance.
- HSP90 stabilization is a key mechanism contributing to resistance.
- Targeting HSP90 may re-sensitize melanoma to BRAF inhibitors.
Conclusions:
- HSP90 represents a promising therapeutic target to overcome BRAF inhibitor resistance in melanoma.
- Early-stage clinical trials are needed to validate HSP90-targeted approaches.
- Randomized trials may be required to confirm the efficacy of combining BRAF and HSP90 inhibition.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Shock Waves
When the source's speed approaches the speed of sound, constructive interference between successive wavefronts emitted by the source occurs immediately behind it. Initially, scientists believed that this constructive interference would result in such high...
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...

